阿尔茨海默病治疗药物研发全面受挫及其思考
发布时间：2018-11-19 11:35
【摘要】：以往30年中针对众多靶点的阿尔茨海默病(AD)治疗药物的研发,虽然全球药业公司、政府、研究机构、大学和风险投资机构等都投入了大量的人力物力资源,但2003年以来FDA没有批准一个AD药物上市。究其原因,固然与无法早期诊断、治疗策略欠佳及患者的遗传多态性带来药物反应的多样性等因素有关,更主要的原因可能是对包括AD在内的许多复杂性疾病发病机制的了解还很肤浅。继续按照目前思路针对单个靶点的AD药物研发可能不是明智的做法。系统生物医学等发展为认知疾病网络机制及基于系统药理学的多靶点药物研发带来了希望;建立在深入的基础研究水平上的神经干细胞移植或小分子药物影响神经干细胞再生可能成为AD治疗的新途径;生物标志物的发现为研究AD发病机制及新型药物研发将带来启迪。
[Abstract]:Over the past 30 years, many targets have been developed for Alzheimer's disease (AD), although global pharmaceutical companies, governments, research institutions, universities and venture capital firms have invested a lot of human and material resources. But FDA has not approved a AD drug since 2003. The reasons are, of course, related to the lack of early diagnosis, poor treatment strategies and the diversity of drug reactions brought about by genetic polymorphisms in patients. The main reason may be that knowledge of the pathogenesis of many complex diseases, including AD, is superficial. It may not be wise to continue to target individual AD drugs on current thinking. The development of system biomedicine brings hope to the network mechanism of cognitive disease and the research and development of multi-target drugs based on systematic pharmacology. Neural stem cell transplantation or small molecule drugs which are based on the basic research level may be a new way to treat AD. The discovery of biomarkers will enlighten the study of the pathogenesis of AD and the development of new drugs.
【作者单位】： 上海交通大学药学院;
【基金】：国家自然科学基金资助项目(81270432)
【分类号】：R96;R749.16
[Abstract]:Over the past 30 years, many targets have been developed for Alzheimer's disease (AD), although global pharmaceutical companies, governments, research institutions, universities and venture capital firms have invested a lot of human and material resources. But FDA has not approved a AD drug since 2003. The reasons are, of course, related to the lack of early diagnosis, poor treatment strategies and the diversity of drug reactions brought about by genetic polymorphisms in patients. The main reason may be that knowledge of the pathogenesis of many complex diseases, including AD, is superficial. It may not be wise to continue to target individual AD drugs on current thinking. The development of system biomedicine brings hope to the network mechanism of cognitive disease and the research and development of multi-target drugs based on systematic pharmacology. Neural stem cell transplantation or small molecule drugs which are based on the basic research level may be a new way to treat AD. The discovery of biomarkers will enlighten the study of the pathogenesis of AD and the development of new drugs.
【作者单位】： 上海交通大学药学院;
【基金】：国家自然科学基金资助项目(81270432)
【分类号】：R96;R749.16
【相似文献】
相关期刊论文 前10条
1 汪华侨,范海虹,徐杰,李光武,袁群芳,谢瑶,姚志彬;抗氧化剂TA99系列治疗阿尔茨海默病的实验依据(英文)[J];中国临床康复;2005年13期
2 钱云;张志s，
本文编号：2342190
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2342190.html
最近更新
教材专著
